Systemic Lupus Erythematosus - Pipeline Review, H2 2016

Publisher Name :
Date: 16-Nov-2016
No. of pages: 419
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H2 2016, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape.

Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 22, 31, 36 and 7 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 9 and 1 molecules, respectively.Systemic Lupus Erythematosus.

Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).

  • The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Systemic Lupus Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Systemic Lupus Erythematosus - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
Introduction 7
Systemic Lupus Erythematosus Overview 8
Therapeutics Development 9
Systemic Lupus Erythematosus - Therapeutics under Development by Companies 11
Systemic Lupus Erythematosus - Therapeutics under Investigation by Universities/Institutes 16
Systemic Lupus Erythematosus - Pipeline Products Glance 17
Systemic Lupus Erythematosus - Products under Development by Companies 20
Systemic Lupus Erythematosus - Products under Investigation by Universities/Institutes 27
Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development 28
Systemic Lupus Erythematosus - Therapeutics Assessment 105
Drug Profiles 121
Systemic Lupus Erythematosus - Dormant Projects 381
Systemic Lupus Erythematosus - Discontinued Products 390
Systemic Lupus Erythematosus - Product Development Milestones 392
Appendix 405

List of Tables

Number of Products under Development for Systemic Lupus Erythematosus, H2 2016 22
Number of Products under Development for Systemic Lupus Erythematosus - Comparative Analysis, H2 2016 23
Number of Products under Development by Companies, H2 2016 24
Number of Products under Development by Companies, H2 2016 (Contd..1) 25
Number of Products under Development by Companies, H2 2016 (Contd..2) 26
Number of Products under Development by Companies, H2 2016 (Contd..3) 27
Number of Products under Development by Companies, H2 2016 (Contd..4) 28
Number of Products under Investigation by Universities/Institutes, H2 2016 29
Comparative Analysis by Late Stage Development, H2 2016 30
Comparative Analysis by Clinical Stage Development, H2 2016 31
Comparative Analysis by Early Stage Development, H2 2016 32
Products under Development by Companies, H2 2016 33
Products under Development by Companies, H2 2016 (Contd..1) 34
Products under Development by Companies, H2 2016 (Contd..2) 35
Products under Development by Companies, H2 2016 (Contd..3) 36
Products under Development by Companies, H2 2016 (Contd..4) 37
Products under Development by Companies, H2 2016 (Contd..5) 38
Products under Development by Companies, H2 2016 (Contd..6) 39
Products under Investigation by Universities/Institutes, H2 2016 40
Systemic Lupus Erythematosus - Pipeline by AbbVie Inc, H2 2016 41
Systemic Lupus Erythematosus - Pipeline by Ablynx NV, H2 2016 42
Systemic Lupus Erythematosus - Pipeline by ACEA Biosciences, Inc., H2 2016 43
Systemic Lupus Erythematosus - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 44
Systemic Lupus Erythematosus - Pipeline by Actelion Ltd, H2 2016 45
Systemic Lupus Erythematosus - Pipeline by AiCuris GmbH and Co KG, H2 2016 46
Systemic Lupus Erythematosus - Pipeline by Amgen Inc., H2 2016 47
Systemic Lupus Erythematosus - Pipeline by Anthera Pharmaceuticals Inc, H2 2016 48
Systemic Lupus Erythematosus - Pipeline by Argos Therapeutics, Inc., H2 2016 49
Systemic Lupus Erythematosus - Pipeline by Asahi Kasei Pharma Corp., H2 2016 50
Systemic Lupus Erythematosus - Pipeline by Astellas Pharma Inc., H2 2016 51
Systemic Lupus Erythematosus - Pipeline by Aurinia Pharmaceuticals Inc, H2 2016 52
Systemic Lupus Erythematosus - Pipeline by Azano Pharmaceuticals Inc., H2 2016 53
Systemic Lupus Erythematosus - Pipeline by Biogen Inc, H2 2016 54
Systemic Lupus Erythematosus - Pipeline by Biotest AG, H2 2016 55
Systemic Lupus Erythematosus - Pipeline by Boehringer Ingelheim GmbH, H2 2016 56
Systemic Lupus Erythematosus - Pipeline by Bristol-Myers Squibb Company, H2 2016 57
Systemic Lupus Erythematosus - Pipeline by Celgene Corporation, H2 2016 58
Systemic Lupus Erythematosus - Pipeline by Cellular Biomedicine Group, Inc., H2 2016 59
Systemic Lupus Erythematosus - Pipeline by CuraVac, Inc., H2 2016 60
Systemic Lupus Erythematosus - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 61
Systemic Lupus Erythematosus - Pipeline by Deltanoid Pharmaceuticals Inc., H2 2016 62
Systemic Lupus Erythematosus - Pipeline by Eisai Co., Ltd., H2 2016 63
Systemic Lupus Erythematosus - Pipeline by Eli Lilly and Company, H2 2016 64
Systemic Lupus Erythematosus - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 65
Systemic Lupus Erythematosus - Pipeline by Genentech Inc, H2 2016 66
Systemic Lupus Erythematosus - Pipeline by Genosco, H2 2016 67
Systemic Lupus Erythematosus - Pipeline by Genovax S.r.l., H2 2016 68
Systemic Lupus Erythematosus - Pipeline by GlaxoSmithKline Plc, H2 2016 69
Systemic Lupus Erythematosus - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 70
Systemic Lupus Erythematosus - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 71
Systemic Lupus Erythematosus - Pipeline by Iltoo Pharma, H2 2016 72
Systemic Lupus Erythematosus - Pipeline by ImmuNext, Inc., H2 2016 73
Systemic Lupus Erythematosus - Pipeline by Immungenetics AG, H2 2016 74
Systemic Lupus Erythematosus - Pipeline by Immunomedics, Inc., H2 2016 75
Systemic Lupus Erythematosus - Pipeline by Immupharma Plc, H2 2016 76
Systemic Lupus Erythematosus - Pipeline by Invion Limited, H2 2016 77
Systemic Lupus Erythematosus - Pipeline by Johnson & Johnson, H2 2016 78
Systemic Lupus Erythematosus - Pipeline by Kadmon Corporation, LLC, H2 2016 79
Systemic Lupus Erythematosus - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 80
Systemic Lupus Erythematosus - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016 81
Systemic Lupus Erythematosus - Pipeline by KPI Therapeutics, Inc., H2 2016 82
Systemic Lupus Erythematosus - Pipeline by Lead Discovery Center GmbH, H2 2016 83
Systemic Lupus Erythematosus - Pipeline by LSK BioPartners, Inc., H2 2016 84
Systemic Lupus Erythematosus - Pipeline by MacroGenics, Inc., H2 2016 85
Systemic Lupus Erythematosus - Pipeline by MedAnnex Ltd, H2 2016 86
Systemic Lupus Erythematosus - Pipeline by Medestea Research & Production S.p.A., H2 2016 87
Systemic Lupus Erythematosus - Pipeline by MedImmune LLC, H2 2016 88
Systemic Lupus Erythematosus - Pipeline by Merck KGaA, H2 2016 89
Systemic Lupus Erythematosus - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 90
Systemic Lupus Erythematosus - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 91
Systemic Lupus Erythematosus - Pipeline by Mount Tam Biotechnologies Inc, H2 2016 92
Systemic Lupus Erythematosus - Pipeline by Neovacs SA, H2 2016 93
Systemic Lupus Erythematosus - Pipeline by Nippon Chemiphar Co., Ltd., H2 2016 94
Systemic Lupus Erythematosus - Pipeline by Nuevolution AB, H2 2016 95
Systemic Lupus Erythematosus - Pipeline by Omeros Corporation, H2 2016 96
Systemic Lupus Erythematosus - Pipeline by Parvus Therapeutics, Inc., H2 2016 97
Systemic Lupus Erythematosus - Pipeline by Pfizer Inc., H2 2016 98
Systemic Lupus Erythematosus - Pipeline by Principia Biopharma Inc., H2 2016 99
Systemic Lupus Erythematosus - Pipeline by Ra Pharmaceuticals, Inc., H2 2016 100
Systemic Lupus Erythematosus - Pipeline by RedHill Biopharma Ltd., H2 2016 101
Systemic Lupus Erythematosus - Pipeline by Redx Pharma Plc, H2 2016 102
Systemic Lupus Erythematosus - Pipeline by Resolve Therapeutics, LLC, H2 2016 103
Systemic Lupus Erythematosus - Pipeline by Sanofi, H2 2016 104
Systemic Lupus Erythematosus - Pipeline by Sarepta Therapeutics, Inc., H2 2016 105
Systemic Lupus Erythematosus - Pipeline by SBI Biotech Co., Ltd., H2 2016 106
Systemic Lupus Erythematosus - Pipeline by Seattle Genetics, Inc., H2 2016 107
Systemic Lupus Erythematosus - Pipeline by Shire Plc, H2 2016 108
Systemic Lupus Erythematosus - Pipeline by Stemline Therapeutics, Inc., H2 2016 109
Systemic Lupus Erythematosus - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 110
Systemic Lupus Erythematosus - Pipeline by TheraMAB LLC, H2 2016 111
Systemic Lupus Erythematosus - Pipeline by Therapix Biosciences Ltd., H2 2016 112
Systemic Lupus Erythematosus - Pipeline by Thunderbolt Pharma Inc, H2 2016 113
Systemic Lupus Erythematosus - Pipeline by TxCell SA, H2 2016 114
Systemic Lupus Erythematosus - Pipeline by UCB SA, H2 2016 115
Systemic Lupus Erythematosus - Pipeline by Xencor, Inc., H2 2016 116
Systemic Lupus Erythematosus - Pipeline by XTL Biopharmaceuticals Ltd, H2 2016 117
Assessment by Monotherapy Products, H2 2016 118
Assessment by Combination Products, H2 2016 119
Number of Products by Stage and Target, H2 2016 121
Number of Products by Stage and Mechanism of Action, H2 2016 126
Number of Products by Stage and Route of Administration, H2 2016 131
Number of Products by Stage and Molecule Type, H2 2016 133
Systemic Lupus Erythematosus - Dormant Projects, H2 2016 394
Systemic Lupus Erythematosus - Dormant Projects (Contd..1), H2 2016 395
Systemic Lupus Erythematosus - Dormant Projects (Contd..2), H2 2016 396
Systemic Lupus Erythematosus - Dormant Projects (Contd..3), H2 2016 397
Systemic Lupus Erythematosus - Dormant Projects (Contd..4), H2 2016 398
Systemic Lupus Erythematosus - Dormant Projects (Contd..5), H2 2016 399
Systemic Lupus Erythematosus - Dormant Projects (Contd..6), H2 2016 400
Systemic Lupus Erythematosus - Dormant Projects (Contd..7), H2 2016 401
Systemic Lupus Erythematosus - Dormant Projects (Contd..8), H2 2016 402
Systemic Lupus Erythematosus - Discontinued Products, H2 2016 403
Systemic Lupus Erythematosus - Discontinued Products (Contd..1), H2 2016 404

List of Figures

Number of Products under Development for Systemic Lupus Erythematosus, H2 2016 22
Number of Products under Development for Systemic Lupus Erythematosus - Comparative Analysis, H2 2016 23
Number of Products under Development by Companies, H2 2016 24
Number of Products under Investigation by Universities/Institutes, H2 2016 29
Comparative Analysis by Late Stage Development, H2 2016 30
Comparative Analysis by Clinical Stage Development, H2 2016 31
Comparative Analysis by Early Stage Products, H2 2016 32
Assessment by Monotherapy Products, H2 2016 118
Number of Products by Top 10 Targets, H2 2016 120
Number of Products by Stage and Top 10 Targets, H2 2016 120
Number of Products by Top 10 Mechanism of Actions, H2 2016 125
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 125
Number of Products by Routes of Administration, H2 2016 130
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 130
Number of Products by Top 10 Molecule Types, H2 2016 132
Number of Products by Stage and Top 10 Molecule Types, H2 2016 132
  • Global Autoimmune Partnering 2010-2017: Deal trends, players and financials
    Published: 01-Nov-2017        Price: US 2995 Onwards        Pages: 700
    "Delivery of this report will take 1-3 days after purchase." Global Autoimmune Partnering 2010 to 2017 provides the full collection of Autoimmune disease deals signed between the world's pharmaceutical and biotechnology companies since 2010. Trends in Autoimmune partnering deals Financial deal terms for headline, upfront and royalty by stage of development Autoimmune partnering agreement structure Autoimmune partnering contract ......
  • Celiac Disease - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Celiac Disease - Market Insights, Epidemiology and Market Forecast - 2025" Reports provides an overview of the disease and global market size of the Celiac Disease for the 7MM (United States, Germany, France, Italy, Spain and UK). The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Celiac Disease forecasted market share for ten years to 2025 segmented by seven major markets. In addition, the report includes the historical and forecas......
  • Celiac Disease - Pipeline Insight, 2017
    Published: 01-Nov-2017        Price: US 1250 Onwards        Pages: 50
    DelveInsight's, " Celiac Disease -Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this Celiac Disease. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Celiac Disease. This report provides information on the therapeutic development for Celiac Disease, dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical, pre-clinical as well ......
  • Graves Disease -Epidemiology Forecast to 2025
    Published: 01-Nov-2017        Price: US 2750 Onwards        Pages: 40
    DelveInsight "Graves Disease - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Graves Disease in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Graves Disease prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Grav......
  • Graves Disease - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Graves Disease - Market Insights, Epidemiology and Market Forecast - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Graves Disease - Market Insights, Epidemiology and Market Forecast for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, tr......
  • Celiac Disease - Epidemiology Insights to 2025
    Published: 05-Jul-2017        Price: US 2950 Onwards        Pages: 40
    DelveInsight " Celiac Disease - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Celiac Disease in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Celiac Disease prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Celiac......
  • Autoimmune Drugs Industry Forecasts - China Focus
    Published: 15-May-2017        Price: US 1800 Onwards        Pages: 78
    This study focuses on China's Autoimmune Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and services. Th......
  • Autoimmune Drugs Companies in China
    Published: 15-May-2017        Price: US 1800 Onwards        Pages: 71
    This study focuses on China's Autoimmune Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of......
  • Autoimmune Drugs Markets in China
    Published: 15-May-2017        Price: US 4000 Onwards        Pages: 201
    China's demand for Autoimmune Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, indu......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs